Anaplastic Large Cell Lymphoma

  • Austin KimEmail author
  • Eric Jacobsen


Anaplastic large cell lymphoma (ALCL) is one of the most common subtypes of peripheral T-cell lymphomas (PTCLs). ALCL is an aggressive lymphoma with anaplastic lymphoma kinase-positive (ALK-positive) ALCL generally having a better prognosis and occurring in younger patients than ALK-negative ALCL. Multiagent chemotherapy, now with the addition of brentuximab vedotin, an anti-CD30 monoclonal antibody-drug conjugate, is the recommended initial therapy for ALCL with high-dose chemotherapy and autologous stem cell rescue reserved for consolidation of patients at high risk of relapse. Novel treatments targeting the universally expressed surface receptor on ALCL cells, CD30, and the ALK tyrosine kinase receptor inhibitors have provided patients with relapsed or refractory ALCL more effective treatment options.


Anaplastic large cell lymphoma (ALCL) Anaplastic lymphoma kinase (ALK) ALK-positive ALCL ALK-negative ALCL Brentuximab vedotin (BV) CD30 


  1. 1.
    Vose JM, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–30.CrossRefGoogle Scholar
  2. 2.
    Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood. 1999;93(8):2697–706.PubMedGoogle Scholar
  3. 3.
    Amin HM, Lai R. Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood. 2007;110(7):2259–67.CrossRefGoogle Scholar
  4. 4.
    Ellin F, Landström J, Jerkeman M, et al. Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study. Blood. 2015;126(1):36–41.CrossRefGoogle Scholar
  5. 5.
    Chihara D, Fanale MA, Miranda RN, et al. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. PLoS One. 2018;13(3):e0191461.CrossRefGoogle Scholar
  6. 6.
    Jacobsen E. Anaplastic large-cell lymphoma, T-/null-cell type. Oncologist. 2006;11:831–40.CrossRefGoogle Scholar
  7. 7.
    Filippa DA, Ladanyi M, Wollner N, et al. CD30 (Ki-1)-positive malignant lymphomas: clinical, immunophenotypic, histologic, and genetic characteristics and differences with Hodgkin’s disease. Blood. 1996;87(7):2906–17.CrossRefGoogle Scholar
  8. 8.
    Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues, vol. 2. 4th ed. Geneva: International Agency for Research on Cancer; 2008.Google Scholar
  9. 9.
    Swedlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.CrossRefGoogle Scholar
  10. 10.
    Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12):5496–504.CrossRefGoogle Scholar
  11. 11.
    Sibon D, Fournier M, Briere J, et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte trials. J Clin Oncol. 2012;30(32):3939–46.CrossRefGoogle Scholar
  12. 12.
    Parrilla Castellar ER, Jaffe ES, Said JW, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124(9):1473–80.CrossRefGoogle Scholar
  13. 13.
    Schmitz N, Trümper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Study Group. Blood. 2010;116(18):3418–25.CrossRefGoogle Scholar
  14. 14.
    Ellin F, Landström J, Jerkeman M, et al. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124(10):1570–7.CrossRefGoogle Scholar
  15. 15.
    Horwitz S, O’Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomized, phase 3 trial. Lancet. 2019;393(10168):229–40. Scholar
  16. 16.
    Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190–6.CrossRefGoogle Scholar
  17. 17.
    Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130(25):2709–17.CrossRefGoogle Scholar
  18. 18.
    Gambacorti Passerini C, Farina F, Stasia A, et al. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patient. J Natl Cancer Inst. 2014;106(2):djt378.CrossRefGoogle Scholar
  19. 19.
    Gambacorti Passerini C, Mussolin L, Brugieres L, et al. Abrupt relapse of ALK-positive lymphoma after discontinuation of crizotinib. N Engl J Med. 2016;374(1):95–6.CrossRefGoogle Scholar
  20. 20.
    Richly H, Kim TM, Schuler M, et al. Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma. Blood. 2015;126(10):1257–8.CrossRefGoogle Scholar
  21. 21.
    Malik SM, Liu K, Qiang X, et al. Folotyn (pralatrexate injection) for the treatment of patients with elapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res. 2010;16(20):4921–7.CrossRefGoogle Scholar
  22. 22.
    Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30:631–6.CrossRefGoogle Scholar
  23. 23.
    Amengual JE, Lichtenstein R, Lue J, et al. A phase I study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood. 2018;131(4):397–407.CrossRefGoogle Scholar
  24. 24.
    O’Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33:2492–9.CrossRefGoogle Scholar
  25. 25.
    Damaj G, Gressin R, Bouabdallah K, et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol. 2012;31:104–10.CrossRefGoogle Scholar
  26. 26.
    Ceritinib with brentuximab vedotin in treating patients with ALK-positive anaplastic large cell lymphoma [Internet] 2016 Apr 6 [updated 2018 Jan 12; cited 2018 Apr 5]. Available from:
  27. 27.
    Romidepsin and lenalidomide in treating patients with previously untreated peripheral T-cell lymphoma [Internet] 2014 Sept 5 [updated 2018 Jan 9; cited 2018 Apr 5]. Available from:
  28. 28.
    Horwitz SM, Koch R, Porcu P, et al. Activity of the PI3K- δ, γ inhibitor duvelisib in a phase I trial and preclinical models of T-cell lymphoma. Blood. 2018;131(8):888–98.CrossRefGoogle Scholar
  29. 29.
    Oki Y, Haverkos B, Zain JM, et al. Tenalisib, a dual PI3K δ/γ inhibitor: safety and efficacy results from an on-going phase I/Ib study in relapsed/refractory T-cell lymphoma. J Clin Oncol. 2018;36(suppl):abstr 7510.CrossRefGoogle Scholar
  30. 30.
    Trial of duvelisib in combination with either romidepsin or bortezomib in relapsed/refractory T-cell lymphomas [Internet] 2016 May 26 [updated 2018 Feb 23; cited 2018 Apr 5]. Available from:
  31. 31.
    Jacobson C, Kopp N, Layer JV, et al. HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma. Blood. 2016;128(21):2517–26.CrossRefGoogle Scholar
  32. 32.
    Onalespib in treating patients with relapsed or refractory anaplastic large cell lymphoma, mantle cell lymphoma, or diffuse large B-cell lymphoma [Internet] 2015 Oct 9 [updated 2018 Mar 5; cited 2018 Apr 5]. Available from:
  33. 33.
    Study of ruxolitinib in relapsed or refractory T or NK cell lymphoma [Internet] 2016 Nov 28 [updated 2018 Mar 29; cited 2018 Apr 5]. Available from:
  34. 34.
    Hamlin PA, Cheson BD, Farber CM, et al. The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL). J Clin Oncol. 2018;36(suppl):abstr 7511.CrossRefGoogle Scholar
  35. 35.
    Avelumab in relapsed and refractory peripheral T-cell lymphoma (AVAIL-T) [Internet] 2017 Feb 8 [updated 2017 Nov 28; cited 2018 Apr 5]. Available from:
  36. 36.
    Nivolumab in treating patients with relapsed or refractory peripheral T-cell lymphoma [Internet] 2017 Mar 9 [updated 2017 Dec 2; cited 2018 Apr 5]. Available from:
  37. 37.
    Durvalumab with or without lenalidomide in treating patients with relapsed or refractory cutaneous or peripheral T cell lymphoma [Internet] 2017 Jan 5 [updated 2017 Nov 30; cited 2018 Apr 5]. Available from:
  38. 38.
    Study of pembrolizumab combined with decitabine and pralatrexate in PTCL and CTCL [Internet] 2017 Aug 7 [updated 2018 Mar 8; cited 2018 Apr 5]. Available from:
  39. 39.
    Wartewig T, Kurgyis Z, Keppler S, et al. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature. 2017;552(7683):121–5.CrossRefGoogle Scholar
  40. 40.
    Ratner L, Waldmann TA, Janakiram M, et al. Rapid progression of adult T-cell leukemia–lymphoma after PD-1 inhibitor therapy. N Engl J Med. 2018;378(20):1947–8.CrossRefGoogle Scholar
  41. 41.
    ALRN-6924 in patients with advances solid tumors or lymphomas [Internet] 2014 Oct 15 [updated 2017 Jun 27; cited 2018 Apr 9]. Available from:
  42. 42.
    Horwitz SM, Hamadani M, Fanale MA, et al. Interim results from a phase 1 study of ADCT-301 (camidanlumab tesirine) show promising activity of a novel pyrrolobenzodiazepine-based antibody drug conjugate in relapsed/refractory Hodgkin/non-Hodgkin lymphoma. Blood. 2017;130:1510.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Harvard Medical School, Dana-Farber Cancer InstituteBostonUSA

Personalised recommendations